Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
23.6M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
1.02M
-
Shares change
-
-27.9K
-
Total reported value, excl. options
-
$1.83M
-
Value change
-
-$43.1K
-
Number of buys
-
5
-
Number of sells
-
-5
-
Price
-
$1.79
Significant Holders of Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) as of Q2 2023
17 filings reported holding RNTX - Rein Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2023.
Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.02M shares
of 23.6M outstanding shares and own 4.33% of the company stock.
Largest 10 shareholders include Alerce Investment Management, L.P. (830K shares), GEODE CAPITAL MANAGEMENT, LLC (55K shares), VANGUARD GROUP INC (40.5K shares), BLAIR WILLIAM & CO/IL (29.7K shares), KCK LTD. (22.3K shares), HighTower Advisors, LLC (19.2K shares), RENAISSANCE TECHNOLOGIES LLC (15.9K shares), Tower Research Capital LLC (TRC) (3.74K shares), JFS WEALTH ADVISORS, LLC (1.59K shares), and UBS Group AG (1.36K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.